Background: Pulmonary diseases are potentially severe late complications of childhood cancer treatment that increase mortality risk among survivors. This nationwide study assesses the prevalence and incidence of pulmonary diseases in long-term childhood cancer survivors (CCS) and their siblings, and quantifies treatment-related risks.
INTRODUCTION
Pulmonary diseases are potentially severe late complications of childhood cancer treatments. Bleomycin, alkylating agents, radiotherapy to the thorax, and thoracic surgery can lead to restrictive lung disease. 1, 2 Abbreviations: BCNU, carmustine; BMI, body mass index; CCNU, lomustine; CCS, childhood cancer survivors; CCSS, US Childhood Cancer Survivor Study; CNS, central nervous system; CI, confidence interval; Gy, Gray; HSCT, hematopoietic stem cell transplantation; ICCC-3, International Classification of Childhood Cancer, Third edition; ICD-10, International Classification of Diseases and Related Problems, 10th revision; IQR, interquartile range; LCH, Langerhans cell histiocytosis; N, Number; OR, odds ratio; P, P-value; SCCR, Swiss Childhood Cancer Registry; SCCSS, Swiss Childhood Cancer Survivor Study Especially when followed by chronic graft versus host disease, allogeneic hematopoietic stem cell transplantation (HSCT) can cause obstructive lung disease such as bronchiolitis obliterans or restrictive lung disease such as lung fibrosis. 2 Childhood cancer survivors (CCS) have a threefold increased risk for hospitalization for pulmonary diseases and up to 14 times increased risk for late pulmonary death, [3] [4] [5] with pneumonia being particularly common. 6 Impaired lung function has been found in a large proportion of CCS (44-65%) depending on inclusion criteria and type of lung function tests. [7] [8] [9] [10] The US Childhood Cancer Survivor Study (CCSS) included CCS diagnosed between 1970 and 1986 and found more lung fibrosis, recurrent pneumonia, chronic cough, and chest wall abnormalities in CCS than in their siblings. 11, 12 The incidence of pulmonary diseases remained elevated up to 25 years after cancer diagnosis. 13 Data on pulmonary diseases in CCS are nevertheless scarce. Few studies have been conducted in Europe, where treatment protocols differ from those used in the United States. Previous studies have come from selected high-profile clinics, included only certain types of cancer, or CCS treated many years ago (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) ). [11] [12] [13] CCS treated with newer regimens need renewed study.
We employed a nationwide, population-based, prospective cohort study to examine pulmonary disease in Swiss CCS diagnosed between 1976 and 2005. We compared the long-term prevalence of selfreported pneumonia, chest wall abnormalities, lung fibrosis, and emphysema between CCS and their siblings, calculated cumulative incidence of pulmonary disease, and quantified treatment-related risks.
METHODS

Swiss Childhood Cancer Survivor Study
The Swiss Childhood Cancer Registry (SCCR) is a nationwide population-based cancer registry that includes all children and adolescents diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis (LCH) before the age of 21. 14 The Swiss Childhood Cancer Survivor Study (SCCSS) is a long-term follow-up cohort study of all patients registered in the SCCR who have been diagnosed since 1976 and who survived 5 or more years after initial diagnosis of cancer. 15 For this study, we included all CCS, who were diagnosed between 1976 and 2005 and aged ≥16 years at survey.
Between 2007 and 2013, we sent questionnaires to all eligible CCS. Nonresponders received a second copy of the questionnaire 4-6 weeks after the first and, if they still did not answer, were contacted by phone. We asked CCS for consent to contact their siblings as a comparison group. If CCS agreed, we sent the same questionnaire without cancer-related questions to their siblings. Siblings who did not respond to the first questionnaire received a second copy 4-6 weeks later, but we did not contact them by phone. Details of the study design have been published elsewhere. 15 The Ethics Committee of the Canton of Bern granted approval to the SCCR and SCCSS (KEK-BE: 166/2014). In line with this approval, informed consent of registration in the SCCR and corresponding studies, like the SCCSS, is collected at time of cancer diagnosis or later with the reply to the SCCSS survey.
Outcome: pulmonary diseases
The SCCSS questionnaire included a section on pulmonary health similar to United States and British childhood cancer survivor studies. 16, 17 We asked CCS and siblings whether they had ever been diagnosed with pneumonia, chest wall abnormalities, lung fibrosis, or emphysema ( Supplementary Fig. S1 ). We created a summary variable any pulmonary disease that combined all four pulmonary disease outcomes. To assess whether a pulmonary disease had occurred before or after cancer diagnosis, we asked participants for the year of first occurrence.
Pneumonia is associated with a high morbidity and mortality in patients with comorbidities, 18 and CCS have a high burden of comorbidities due to cancer treatment. 9 We increased sensitivity of the questions on pneumonia by asking about both single and repeated events.
Previous studies have only asked about recurrent pneumonia. 11 and ≥40 Gy. 20 We collected information on thoracic surgery (yes/no) and categorized the types of surgery (Supplementary Table S1 ). We assessed whether CCS had an autologous, allogeneic, or no HSCT.
Information on sociodemographic and lifestyle characteristics
From the SCCSS survey, we extracted information on sociodemographic data (gender, age at survey, Swiss language region, migration background) and lifestyle (body mass index [BMI] , smoking status, performing sports). We calculated BMI from the survey's self-reported height and weight data. For participants younger than 19 at survey, we calculated BMI z-scores using the Swiss references. 21 BMI at survey was classified as underweight (>19 years, <18 kg/m 2 ; ≤19 years, <-2 z-scores), normal weight (>19 years, ≥18 to <25 kg/m 2 ; ≤19 years, ≥-2 to ≤1 z-score), overweight/obese (>19 years, ≥25 kg/m 2 ; ≤19 years, >1 z-score). 22, 23 We categorized smoking status as never smoker, ex-smoker, and current smoker. We defined performing sports as engagement in at least moderate gym or sports activity for more than 1 hr/week.
Statistical analysis
We compared long-term prevalence of self-reported pulmonary diseases between CCS and siblings ever in life using chi-squared tests.
For better comparison between CCS and siblings, we standardized siblings for gender, age at survey, Swiss language region, and migration background as described previously. 24, 25 Characteristics of siblings are shown in Supplementary Table S2 .
TA B L E 1 Characteristics of childhood cancer survivors and siblings
Survivors
Siblings To estimate the cumulative incidence of pulmonary disease, we used the Kaplan-Meier method. We assessed the first occurrence of any pulmonary disease separately and combined for each specific disease.
For pneumonia, we also computed cumulative incidence curves for different cancer treatments. We used log-rank tests to test for equivalence of incidence curves. Start of follow-up time was age at cancer diagnosis for CCS, and for siblings mean age at cancer diagnosis of CCS. End of follow-up time was either the year of disease occurrence or time of survey completion if participants had no pulmonary disease.
We imputed age at pulmonary disease if a participant reported a pulmonary disease but not the year of first occurrence using observed values (in CCS gender, age at survey, smoking status, age at cancer diagnosis, cancer diagnosis, radiotherapy to the thorax, and pulmotoxic chemotherapy; and in siblings gender, age at survey, smoking status;
Supplementary text). 26 Controls were censored at time of survey if they had no pulmonary disease.
For CCS, we quantified treatment-related risks by using uniand multivariable logistic regressions. Explanatory factors were pulmotoxic chemotherapy (nitrosoureas, busulfan, or bleomycin), radiotherapy to the thorax, thoracic surgery, and HSCT. We used likelihood ratio tests to assess whether explanatory variables were associated with pulmonary diseases. We adjusted for the following confounding factors mentioned in the literature: gender, age at diagnosis, smoking status, performing sport, and BMI at survey. [27] [28] [29] We used R 3. Table S2 ).
RESULTS
Characteristics of study population
Fifty-three percent of CCS were male, median (interquartile range
[IQR]) age at survey was 27 years (20-32) ( Table 1 ). CCS performed less sport than siblings (60% vs. 67%, P = 0.001) and were more often underweight (6% vs. 3%, P = 0.004). Median (IQR) age at cancer diagnosis was 9 years (4-14); median time since diagnosis (IQR) was 18 years (13-23); common diagnoses were leukemia (32%), lymphoma (20%), and CNS tumors (14%). Eighty-two percent had been treated with chemotherapy and 8% had received pulmotoxic chemotherapy:
1% busulfan, 2% nitrosoureas, and 5% bleomycin. Fifteen percent of CCS had received radiotherapy to the thorax, the majority with doses between 20 and 39 Gy (8%). Four percent had thoracic surgery, and 5%
had received HSCT (3% autologous and 2% allogeneic; Table 1, Supplementary Table S2 ).
Prevalence of pulmonary diseases in CCS and siblings
Long-term prevalence of any pulmonary disease was higher in CCS than in siblings (12% vs. 7%, P = 0.001; Table 2 , Supplementary Fig. S3 ).
The difference in long-term prevalence of pneumonia ever in life was marked, 10% versus 7% (P = 0.020), and 3% of CCS compared to 1.5% of siblings had one pneumonia, and 0.8% vs. 0% had two or more pneumonias (overall, P = 0.006) in the last 2 years (Table 2) . When stratified by pulmotoxic treatment, CCS treated with no pulmotoxic treatment, pulmotoxic chemotherapy alone and both pulmotoxic chemotherapy and radiotherapy to the thorax had a higher long-term prevalence of pneumonia than siblings (10% vs. 7%, P = 0.048, 15%, P = 0.042; and 14%, P = 0.014, respectively; Supplementary (Table 3 ).
Cumulative incidence of pulmonary disease after cancer diagnosis
Over 35 years of follow-up, 21% (95% confidence interval [CI] 15-28%) of CCS had developed at least one pulmonary disease (Fig. 1) .
The cumulative incidence was highest for pneumonia (18%, 95% CI 13-24%), lower for chest wall abnormalities (4%, 95% CI 2-9%) and lung fibrosis (3%, 95% CI 1-14%), and lowest for emphysema (0.2%, 95% CI 0.1-0.6%).
Cumulative incidence of pneumonia by treatment group
Cumulative incidence of pneumonia in CCS within 25 years of followup differed by treatment group (Fig. 2) : CCS without pulmotoxic treatment and those with radiotherapy to the thorax only had a similar cumulative incidence of pneumonia as siblings (Panel A, 11%, 95% CI 9-14% vs. 9%, 95% CI 7-11%, P = 0.074; Panel B, 12%, 95% CI 7-19% vs. 9%, 95% CI 7-11%, P = 0.226). The graph suggests a trend, though it is not statistically significant, for increasing risk among those treated with radiotherapy to the thorax starting approximately 20 years after diagnosis. CCS treated with pulmotoxic chemotherapy had a higher cumulative incidence than siblings (Panel C, 18%, 95% CI 9-33% vs. 9%, 95% CI 7-11%, P = 0.014), starting soon after treatment.
CCS treated with both pulmotoxic chemotherapy and radiotherapy to the thorax had the highest cumulative incidence (Panel D, 23%, 95% CI 13-38% vs. 9%, 95% CI 7-11%, P = 0.001) differing from siblings.
Risk factors for pulmonary disease
CCS treated with busulfan were more likely to develop pneumonia significant. Of the assessed life style characteristics, only underweight was associated with lung fibrosis (OR 6.1, 95% CI 1.7-24.9).
Results from univariable regression (unadjusted) are given in Supplementary Table S5 .
DISCUSSION
Pulmonary diseases, particularly pneumonia and chest wall abnormalities, were increased in this nationwide, population-based comparison of CCS with their siblings. Busulfan was associated with pneumonia, and thoracic surgery with chest wall abnormalities and lung fibrosis.
Cumulative incidence of all pulmonary diseases after cancer diagnosis continued to increase throughout life without reaching a plateau 25 years after diagnosis. Cumulative incidence of pneumonia differed by cancer treatment, with the highest incidence in those treated with both pulmotoxic chemotherapy and radiotherapy to the chest.
The Childhood Cancer Survivor Study is a multicenter cohort study that also used patient-reported data and found a slightly increased cumulative incidence of pulmonary disease in CCS compared to siblings, 30% vs. 27% (P < 0.001). 11, 13 The lower long-term prevalence in our study, 12%, is explained by our exclusion of asthma and chronic cough, which are very common in the general population (Supplementary text). The CCSS, which included patients diagnosed from 1970 to 1986 found fewer chest wall abnormalities (2.2% vs. 1.3%), and more lung fibrosis than we did (0.8% vs. 3.1%). 11 This might be because Swiss CCS were younger and the development of lung fibrosis can occur with a latency of up to 25 years, 13 or because the Swiss cohort was treated with treatment protocols of more recent years, including lower radiation doses and volumes, as, for example, in CCS F I G U R E 1 Cumulative incidence of self-reported pulmonary diseases in survivors during follow-up. Imputation was used for missing year of onset of pulmonary disease. Time of onset of pulmonary disease was reported as years of follow-up. Start of follow-up time was individual age at cancer diagnosis for survivors and for siblings we used mean age at cancer diagnosis of survivors. Any pulmonary disease refers to the first occurrence of the disease. If a survivor reported more than one pulmonary disease, only the first occurrence was counted.
of Hodgkins Lymphoma. 30 These assumptions are supported by the observed lower long-term prevalence of lung fibrosis diagnosed in Swiss CCS in recent years. The proportion of CCS in our study who had repeated pneumonia within the previous 2 years is comparable to that in the CCSS. 11 Because pneumonia is associated with high morbidity and mortality in patients with comorbidities, 18 we also looked at all events of pneumonia and found that 10% of CCS had pneumonia at some time, while the long-term prevalence was 7% in their siblings. The F I G U R E 3 Associations between cancer treatments and selfreported pulmonary diseases occurring after cancer diagnosis. Multivariable logistic regression adjusted for all treatment factors shown and gender, age at diagnosis, smoking status, BMI at survey, and performing sports. n.a., not applicable prevalence of pneumonia did not decrease in CCS diagnosed in recent years. The cumulative incidence of pneumonia increased over the 25-year follow-up without plateauing. Dietz et al. reported the same for recurrent pneumonia. 13 The CCSS identified different risk factors for pneumonia, radiotherapy to the thorax, and HSCT, 11, 13 while in our study pneumonia risk was higher after busulfan treatment. We also observed that cumulative incidence of pneumonia differed by treatment groups and was highest in those treated with both pulmotoxic chemotherapy and radiotherapy to the thorax. HSCT with subsequent graft versus host disease and immunodeficiency could explain development of repeated infections such as pneumonia. 6, 31 However, F I G U R E 2 Cumulative incidence of self-reported pneumonia in years of follow-up in survivors by treatment group and siblings. Start of follow-up time was individual age at cancer diagnosis for survivors and for siblings we used mean age at cancer diagnosis of survivors. CT, chemotherapy; RT, radiotherapy our multivariable analysis found no evidence that the association between pneumonia and busulfan was mediated via HSCT (the effect of busulfan was not reduced when we adjusted for HSCT). We found also no evidence for an independent effect of HSCT on risk of pneumonia. Therefore, our results suggest that busulfan itself has a longterm effect on the immune system or lung tissues. We do not know the underlying mechanisms, as the few experimental data from animal models and cell culture studies have focused on short-term effects. The risk for chest wall abnormalities and lung fibrosis was higher in CCS treated with radiotherapy to the thorax and thoracic surgery, which also is similar to CCSS findings. [11] [12] [13] We found a higher proportion of pulmonary disease in CCS treated with alkylating agents (busulfan) or surgery to the lungs as was also reported by Record et al. 7 Lung fibrosis was associated with underweight at survey. We think this might be a secondary effect, because CCS with lung fibrosis are more likely to be sick and thus more often suffer from malnutrition and have elevated exertion because of difficulties with breathing, as hypothesized in adult idiopathic lung fibrosis patients. 32 Finally, up to 65% of CCS have been found to have impaired lung function. [7] [8] [9] [10] This rate is higher than the cumulative, overall incidence of disease in our study because lung function tests may indicate subclinical pathology possibly well in advance of diagnosis of disease.
Strengths of our study are the population-based nature and the high response rate that make our study population representative for the entire population of Swiss CCS. Nonresponse bias seems to play a minor role in the SCCSS. We recently assessed the difference in typical prevalence estimates (somatic health, medical care, mental health, health behaviors) among early responders (40%), all responders (69%), and a complete representative population constructed with inverse probability weighting (100%). 33 We found similar results among those populations, suggesting that prevalence estimates in participants are close to the true prevalence in the total population. 33 Further, we have no evidence that CCS reported differently than their siblings: asthma and chronic cough, common disorders not specifically caused by cancer treatment, 34 were reported equally often (Supplementary text). Our study covers all cancer diagnoses and treatment periods from 1976 to 2005, while previous studies often focused only on specific diagnostic groups 12, 35 and CCS diagnosed until 1986. 11, 13 Last, the SCCSS assessed a large number of sociodemographic and life-style characteristics, which we could include in the analyses.
The limited sensitivity and specificity of self-reported disease could have biased our results. However, one study's comparison of selfreports of pulmonary diseases including pneumonia, lung fibrosis, and emphysema to information from medical records of CCS of HSCT has shown good validity (96% sensitivity, 91% specificity). 36 We could not determine if the effects of drugs or radiotherapy to the thorax were dose dependent, as we did not have exact cumulative doses of chemotherapeutic drugs and numbers of patients with pulmonary outcomes were too low to stratify them into more categories. Due to survival bias, our results might underestimate the true prevalence. The absolute numbers of CCS with pulmonary disease was small, because our study population was young, and incidence of pulmonary disease increases over the life of CCS. 5, 13 CCS are at increased risk of pneumonia, which is the most common pulmonary cause of death among CCS. 6 The underlying causes of this are poorly understood. The long-term prevalence of pneumonia remained increased among CCS diagnosed in recent years and treated with newer treatment protocols. Future research should investigate pathophysiological mechanisms leading to pneumonia in CCS. Lung fibrosis and emphysema are rare; to evaluate associations with cancer treatment, international data must be pooled. The increased incidence of pulmonary disease, particularly pneumonia, continues throughout the life of a CCS, and the risk depends on the type of cancer treatment.
We therefore must consider preventive measures for pneumonia such as vaccination for influenza or pneumococcal pneumonia in susceptible CCS. Lifelong clinical monitoring of pulmonary health of former childhood cancer patients at risk for pulmonary disease is necessary.
